L-692429

**L‑692429** is a synthetic small molecule and nonpeptidyl growth hormone secretagogue (GHS) agonist developed by Merck & Co. It acts as an agonist of the ghrelin/growth hormone secretagogue receptor (GHSR), stimulating the release of growth hormone via a mechanism distinct from endogenous growth hormone-releasing hormone. The compound was designed as a nonpeptide mimic of GH-releasing peptide‑6 (GHRP‑6), showing dose-dependent stimulation of growth hormone secretion in humans. Clinical development reached Phase 1 for indications such as growth hormone deficiency and dwarfism but was ultimately discontinued[1][4][6][8].

Other names

3-amino-3-methyl-N-[(3R)-2-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4,5-dihydro-3H-1-benzazepin-3-yl]butanamideL 692,429L692429 free baseL-692429 free baseL 692429 free base